Activation of @entity12186 / @entity12186 mediates angiogenesis but not XXXX .

@entity455 @entity51034 @entity95 @entity12186 @entity6667 @entity842 @entity741 @entity35 @entity551
OBJECTIVE: The concept of therapeutic angiogenesis with @entity6667 ( @entity6667 ) has been validated in peripheral @entity455 . Its use in @entity741 may be delayed as the result of the description in a porcine model of peripheral vasodilation after intraluminal injections of @entity6667 resulting in a 50% fatality rate by @entity551 . We carried out this study to test whether @entity6667 -induced @entity551 (1) is species specific, (2) is mediated by the receptor mediating angiogenesis, (3) is prevented by inhibition of @entity842 synthase. METHODS: In the @entity95 corneal pocket assay we tested whether a previously published anti-idiotypic antibody (AIA) agonist of the @entity6667 receptor @entity12186 / @entity51034 could elicit angiogenesis. Various doses of recombinant @entity6667 or AIA were injected into anesthetized normotensive @entity35 -Kyoto @entity35 and the mean arterial blood pressure (MABP) was recorded. To test the implication of @entity842 in @entity6667 -induced @entity551 we treated the animals with a competitive inhibitor of @entity842 synthase prior to the injection of @entity6667 . RESULTS: Both @entity6667 and AIA induce angiogenesis but only intravenous injections of @entity6667 induced a rapid, transient and dose-dependent decrease in MABP. The ED50 was 0.5 micrograms. The interval between two @entity6667 injections required to lead to a decrease of MABP was 40 minutes. @entity842 synthesis inhibitor prevented, in a reversible fashion, the effect of @entity6667 . CONCLUSION: @entity6667 -induced @entity551 is not species specific. It is prevented by @entity842 inhibition. @entity6667 -induced angiogenesis and @entity551 are not mediated in vivo by the same @entity6667 receptor.
